Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 14 May 2019, 09:12 HKT/SGT
Share:
    

Source: NEC Corporation
NEC Becomes the First Japanese Company to Join the TESLA Consortium's Fight Against Cancer

TOKYO, May 14, 2019 - (JCN Newswire) - NEC Corporation (TSE: 6701) has become the first Japanese company to join the Tumor neoantigEn SeLection Alliance (TESLA) founded and managed by the Parker Institute for Cancer Immunotherapy and the Cancer Research Institute (CRI). This global bioinformatics collaborative includes scientists from more than 35 of the leading neoantigen research groups in academia, nonprofit and industry. The goal is to find the best algorithms to predict which cancer neoantigens encoded in DNA and RNA can be recognized by and stimulate an immune response.

Individualized neoantigen vaccines, which are tailored to each patient's tumor, are one of most advanced cancer treatments to show great promise for activating the immune system to fight cancer whilst reducing the chances of autoimmune responses.

NEC was accepted into the TESLA consortium given the uniqueness of the company's Neoantigen Prediction System. The prediction system utilizes NEC's cutting-edge AI technology, "NEC the WISE"(1), to identify and prioritize patient-specific neoantigens. NEC comprehensively evaluates candidate neoantigens with a primary focus placed on its in-house MHC-binding affinity prediction. These allow NEC to effectively prioritize the numerous candidate neoantigens identified in a single patient.

"By participating in this consortium, NEC will be able to collaborate with the world's leading research organizations and potentially improve the chances of survival for cancer patients with this new treatment option," said Osamu Fujikawa, Senior Vice President, NEC Corporation. "NEC focuses on the provision of social solutions and continues efforts to strengthen its next-generation healthtech businesses," he added.

(1) NEC the WISE
NEC the WISE is a term for the Company's cutting-edge portfolio of AI technologies.


Contact:
NEC
Seiichiro Toda        
s-toda@cj.jp.nec.com
+81-3-3798-6511


Topic: Press release summary
Source: NEC Corporation

Sectors: Cloud & Enterprise, BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


NEC Corporation Links

http://www.nec.com

https://www.facebook.com/nec.global/

https://twitter.com/NEC_corp

https://www.youtube.com/user/NECglobalOfficial

https://www.linkedin.com/company/nec/

NEC Corporation
July 18, 2025 08:36 HKT/SGT
SJC2 optical submarine cable in operation
July 16, 2025 13:00 HKT/SGT
AUG East Consortium and NEC to develop high-capacity submarine cable system across East Asia
July 4, 2025 12:25 HKT/SGT
Yachiyo Engineering and NEC launch adaptation finance study in Indonesia to calculate the adaptation value of disaster prevention measures
June 23, 2025 18:22 HKT/SGT
Executive Appointments in Connection with the Establishment of NESIC Holdings
June 18, 2025 12:40 HKT/SGT
NEC and Chugai Pharmaceutical use AI to potentially enhance cancer treatment
June 2, 2025 16:56 HKT/SGT
Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 months with Individualized Cancer Vaccine TG4050
May 30, 2025 09:11 HKT/SGT
IFS and NEC Strengthen their Strategic Partnership to Create New Value
Apr 28, 2025 15:03 HKT/SGT
NEC DGDF Headquarters relocates to Zurich to accelerate growth and enhance management globally
Apr 24, 2025 09:23 HKT/SGT
NEC invests in U.S.-based "Geodesic Alliance Fund" aiming to strengthen economic security business
Apr 9, 2025 10:09 HKT/SGT
NEC Face Recognition Ranks First in NIST Accuracy Testing
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: